Back

Intra-coronary imaging before and after PCSK9 inhibition stratified by residual inflammatory risk: a serial imaging sub-study of YELLOW III

28 August 2026 (11:25 - 11:35)
Organised by: Logo
Congress Presentation Part of: New insights into lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Pruthvi C Revaiah

New York (United States of America)

5 More presentations in this session

Presentation thumbnail
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
Professor S. Zhong (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
Doctor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials
Doctor E. Stroes (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Evolocumab and risk of a first myocardial infarction: a prespecified analysis of the VESALIUS-CV trial
Doctor G. De Ferrari (Turin, IT)
Abstract Slides Video
Presentation thumbnail
ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia
Professor S. Tsimikas (La Jolla, US)
Abstract Slides Video

Access the full session

Session thumbnail
New insights into lipid-lowering pharmacotherapy
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:25 CET
You may be interested in
thumbnail
Congress Presentation
Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study
29 August 2026
thumbnail
Congress Presentation
Clinical outcomes according to residual cholesterol and inflammatory risk in patients undergoing PCI
30 August 2024
thumbnail
Congress Presentation
PCSK9i and atherosclerotic plaque regression assessed by coronary computed tomography angiography
31 August 2026
thumbnail
Congress Presentation
State-of-the-art lecture in lipid lowering therapy and the atheroma .
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources